Plain-English translation of NCT07508605 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new immunotherapy called CD19/CD20 CAR/TRuC-T cell therapy for patients whose B-cell lymphoma has stopped responding to earlier treatments. The therapy works by taking your own immune cells, modifying them in the laboratory to recognize and fight lymphoma cells, and then infusing them back into your body. Researchers want to see if this treatment is safe and how well it works against this difficult-to-treat cancer.
Some patients with B-cell lymphoma don't respond well to standard treatments or their cancer comes back after initial therapy. This new treatment is designed to help patients who have exhausted other options, including those whose cancer has become resistant to earlier cell therapies.
You likely qualify if…
You likely don't qualify if…
You would have cells collected from your blood through a special procedure called apheresis. These cells are then sent to a laboratory where they are modified to create the treatment. While this is being prepared, you may receive other supportive care as needed. Once ready, you would receive a single infusion of the modified cells through an IV. After that, you would be monitored closely for safety and effectiveness over the following weeks and months, with blood tests and imaging scans to track how well the treatment is working.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China